Table 2.
PFS
|
OS
|
ORR
|
AEs (Grade ≥3)
|
|||||
---|---|---|---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
1. Bevacizumab in the control group was used | ||||||||
Yes | 0.76 (0.64, 0.90) | 0.001 | 1.06 (0.86, 1.30) | 0.605 | 1.58 (1.08, 2.30) | 0.019 | 1.46 (0.99, 2.17) | 0.058 |
No | 0.53 (0.44, 0.65) | 0.000 | 0.87 (0.71, 1.08) | 0.220 | 4.11 (2.50, 6.78) | 0.000 | 2.68 (1.83, 3.93) | 0.000 |
2. Corticosteroid drug was used, rate (%) | ||||||||
N<50 | 0.58 (0.49, 0.69) | 0.000 | 0.94 (0.77, 1.14) | 0.536 | 2.08 (0.85, 5.08) | 0.108 | 1.90 (0.82, 4.38) | 0.134 |
N>50 | 0.79 (0.63, 0.98) | 0.029 | 0.99 (0.83, 1.12) | 0.921 | 1.92 (1.13, 3.27) | 0.016 | 1.69 (1.10, 2.60) | 0.017 |
Abbreviations: PFS, progression-free survival; OS, overall survival; ORR, object response rate; AEs, adverse events.